JAC Advance Access published online on September 29, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl403
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
* To whom correspondence should be addressed. Objectives: The purpose of this study was to determine the tissue and corresponding serum concentration of tigecycline at selected time points in gall bladder, bile, colon, bone, synovial fluid (SF), lung and CSF in subjects undergoing surgical or medical procedures. Methods: One hundred and four adult subjects (aged 24-83 years; 64 women, 40 men) received a single intravenous (iv) dose of tigecycline (100 mg infused over 30 min). Subjects were randomly assigned to one of four collection times at 4, 8, 12 and 24 h after the start of the infusion. For CSF, samples were collected at approximately 1.5 and 24 h after the start of the infusion. All subjects had serum samples collected before the administration of tigecycline, at the end of the infusion and at the time corresponding to tissue or body fluid collection. Drug concentrations in serum, tissues and body fluids were determined by LC/MS/MS. The area under the mean concentration-time curve from 0 to 24 h (AUC0-24) was determined for the comparison of systemic exposure between tissue or body fluid to serum. Results: The mean serum concentrations of tigecycline were similar to those previously published. Tissue penetration, expressed as the ratio of AUC0-24 in tissue or body fluid to serum, was 537 for bile, 23 for gall bladder, 2.6 for colon, 2.0 for lung, 0.41 for bone, 0.31 for SF and 0.11 for CSF. Conclusions: A single 100 mg dose of intravenous tigecycline produced considerably higher tissue/fluid concentrations in bile, gall bladder, colon and lung compared with simultaneous serum concentrations. On average, the systemic exposure of tigecycline in bone, SF and CSF ranged from 11% to 41% of serum concentrations. The results in bone are inconsistent with previous radiolabelled studies in animals and it is unclear if tight binding to bone (versus low bone uptake) or poor extraction of tigecycline for LC/MS/MS detection or both may have contributed to the differences we observed in humans.
Received April 22, 2006
Revised August 13, 2006
Accepted September 9, 2006
Original article
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose
Keith A. Rodvold 1 *, Mark H. Gotfried 2, Michael Cwik 3, Joan M. Korth-Bradley 4, Gary Dukart 4, and Evelyn J. Ellis-Grosse 4
2 Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA; College of Medicine, The University of Arizona, Phoenix, AZ 85012, USA; Pulmonary Associates, PA, 1112 E McDowell Road, Phoenix, AZ 85006, USA
3 IIT Research Institute, Life Sciences Group, 10 West 35th Street, Chicago, IL 60616, USA
4 Clinical Research, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA
Keith A. Rodvold, E-mail: kar{at}uic.edu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. G. Zhanel, P. J. Baudry, F. Tailor, L. Cox, D. J. Hoban, and J. A. Karlowsky Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum {beta}-lactamases, AmpC {beta}-lactamases and reduced susceptibility to carbapenems using an in vitro model J. Antimicrob. Chemother., October 1, 2009; 64(4): 824 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-L. Ho, V. C.-C. Cheng, and C.-M. Chu Antibiotic Resistance in Community-Acquired Pneumonia Caused by Streptococcus pneumoniae, Methicillin-Resistant Staphylococcus aureus, and Acinetobacter baumannii Chest, October 1, 2009; 136(4): 1119 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Cunha Pharmacokinetic Considerations regarding Tigecycline for Multidrug-Resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii Urosepsis J. Clin. Microbiol., May 1, 2009; 47(5): 1613 - 1613. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Curcio Comment: Tigecycline for the Treatment of Acinetobacter Infections: A Case Series Ann. Pharmacother., November 1, 2008; 42(11): 1717 - 1718. [Full Text] [PDF]
|
|
|
|
|
|
A. P. MacGowan Tigecycline pharmacokinetic/pharmacodynamic update J. Antimicrob. Chemother., September 1, 2008; 62(suppl_1): i11 - i16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 What role for {blacktriangledown}tigecycline in infections? DTB, August 1, 2008; 46(8): 62 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Rubino, L. Ma, S. M. Bhavnani, J. Korth-Bradley, J. Speth, E. Ellis-Grosse, K. R. Rodvold, P. G. Ambrose, and G. L. Drusano Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation Antimicrob. Agents Chemother., November 1, 2007; 51(11): 4085 - 4089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M Slover, K. A Rodvold, and L. H Danziger Tigecycline: A Novel Broad-Spectrum Antimicrobial Ann. Pharmacother., June 1, 2007; 41(6): 965 - 972. [Abstract] [Full Text] [PDF]
|
|